Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.
about
N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectinPrognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo StudyClinical Correlates and Prognostic Value of Plasma Galectin-3 Levels in Degenerative Aortic Stenosis: A Single-Center Prospective Study of Patients Referred for Invasive TreatmentUsefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure.Gene expression changes associated with myocarditis and fibrosis in hearts of mice with chronic chagasic cardiomyopathy.Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure.Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.Cord blood neutrophils display a galectin-3 responsive phenotype accentuated by vaginal delivery.Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).Advances in tenascin-C biology.Effect of postconditioning on dynamic expression of tenascin-C and left ventricular remodeling after myocardial ischemia and reperfusion.Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation.Calciotropic and Phosphaturic Hormones in End-Stage Heart Failure Patients Supported by a Left-Ventricular Assist Device.Influence of Mechanical Circulatory Support on Endothelin Receptor Expression in Human Left Ventricular Myocardium from Patients with Dilated Cardiomyopathy (DCM).Serum Galectin-9 Levels Are Associated with Coronary Artery Disease in Chinese IndividualsGalectin-3: a novel biomarker for the prognosis of heart failure.Serial galectin-3 and future cardiovascular disease in the general population.Galectin-3 in cardiac remodeling and heart failure.Novel biomarkers in human terminal heart failure and under mechanical circulatory support.Matricellular proteins: new molecular targets to prevent heart failure.Personalizing biomarker strategies in heart failure with galectin-3.Clinical utility of biomarkers in chronic kidney disease and chronic heart failure.The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.Biomarkers in mechanical circulatory support.Heart failure and galectin 3.Prognostic value of galectin-3 in patients with heart failure.Interleukin 1 Receptor-Like 1 Protein (ST2) is a Potential Biomarker for Cardiomyopathy in Duchenne Muscular Dystrophy.Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure.Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure.Using galectin-3 to reduce heart failure rehospitalization.The role of tenascin-C in tissue injury and tumorigenesis.Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy-The BIOCRT Study.Value of pentraxin-3 and galectin-3 in acute coronary syndrome: a short-term prospective cohort study.Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function.Cellular, molecular, genomic changes occurring in the heart under mechanical circulatory support.Clinical trials update from the Heart Failure Society of America Meeting 2009: FAST, IMPROVE-HF, COACH galectin-3 substudy, HF-ACTION nuclear substudy, DAD-HF, and MARVEL-1.Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure.Global gene expression analysis in nonfailing and failing myocardium pre- and postpulsatile and nonpulsatile ventricular assist device support.
P2860
Q24651908-807E57BE-185A-4B6D-9DE3-B490F2AC3CD6Q33529398-5493CAA9-9E9D-4E12-8C9B-7FAA03B6690FQ33577541-48A4BEBE-0D8B-441E-8EC9-98CC1A4F5964Q33754895-6A26EFC5-2E2E-479A-88C2-702E0AEFF0AFQ33912126-6535984D-6DFF-47D4-82D7-908FEC6BECE6Q33965302-AAAF9CFF-7F11-46B9-A891-32E21001E53CQ34032111-5A52F98B-AB0B-4199-BE2E-1B7DC357D116Q34528187-9FD4B862-3B64-4ECE-9A97-B20CB6075AF9Q34960351-47C1B5FD-9063-4C9D-96E6-D231D5F05F8BQ35206146-66A3852D-6C1C-41B9-B90B-531243AFC109Q35214557-9C0C40EF-805B-415E-9902-43CBEBEEECFFQ35365832-D62C48D0-33BD-4A80-A11C-E49FFBE377D7Q36052222-55ADEFC9-2679-4668-A4D3-0E1C08D3BB18Q36176069-2196F883-0D5E-43E6-B34E-7E7934C8D6CCQ36251275-508607DB-7DE2-4EA3-B05A-887AE2AEE8F5Q36339546-D771418E-8690-45C3-8B93-D864CCA4A256Q36385583-BADBC01D-E3BC-4DB7-9B1D-FF65866A0A9AQ37580709-776252B7-9663-4711-AD5C-0170D3E0A1DFQ37738648-12C59B2E-E6B2-40A9-B018-F767F7693D70Q37894731-6867C4A7-3C05-4ED4-A1B4-CFD028AB1C24Q37925022-1EDDDB45-1630-41BC-B8FB-B6C4CCB1DCF7Q38062031-35A04D89-BA91-4B19-BD18-287AAF9869CDQ38125509-A4EC12F4-654F-4A7F-B17F-56445DDEEBF6Q38154222-0823D072-2846-49B7-ADE4-7B42CDFB02D9Q38194209-F21AFB86-B472-4EBB-A939-CF0B73DF619BQ38249997-95C9FDCA-0E17-4EE9-B385-D1AD15290963Q38269044-1792FA29-EEA8-4B53-961A-FD33BF276AB1Q38471023-C5823573-E7D8-463C-A374-B29638C1963EQ38640186-E442F624-1F69-4E8C-9BE0-0732C745FAACQ38687046-22F97020-5EC8-44EA-8572-399DF3B84CEEQ38977493-B906713D-F69F-4B92-8DF0-CC254F56F374Q39204234-68BBE265-06B5-4993-8EE6-8D3CD51F2FB0Q39280466-28635D9D-1328-480C-AAE9-D87AE1FDEE00Q40621297-BC42F06B-2025-4680-B6B8-CF7CD8AD50AFQ41151739-1C0C5957-1AD6-45CE-8584-DDB842818176Q42191449-5D9B4068-3FD5-4E81-B806-2FD8ECB59081Q43002918-47EECD92-C3C8-4096-8EAF-97CCD8A69AADQ43204655-5A10C57C-2660-48E1-8F28-6B01E8699403Q44426645-5C26EF3A-B668-447E-8076-9AB708252F26Q45153672-E147247F-5020-4765-9590-48F8EB0348BC
P2860
Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Plasma biomarkers of myocardia ...... l circulatory support devices.
@en
Plasma biomarkers of myocardia ...... l circulatory support devices.
@nl
type
label
Plasma biomarkers of myocardia ...... l circulatory support devices.
@en
Plasma biomarkers of myocardia ...... l circulatory support devices.
@nl
prefLabel
Plasma biomarkers of myocardia ...... l circulatory support devices.
@en
Plasma biomarkers of myocardia ...... l circulatory support devices.
@nl
P2093
P921
P1476
Plasma biomarkers of myocardia ...... l circulatory support devices.
@en
P2093
Aly El Banayosy
Astrid Kassner
Birte Bohms
Frank Kramer
Hamdin Cakar
Hendrik Milting
Lothar Kruska
Martina Klein
Michael Seewald
Peter Ellinghaus
P304
P356
10.1016/J.HEALUN.2008.02.018
P577
2008-06-01T00:00:00Z